MARKET

QURE

QURE

Uniqure
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.15
+0.33
+2.39%
After Hours: 14.15 0 0.00% 16:01 05/17 EDT
OPEN
14.21
PREV CLOSE
13.82
HIGH
14.36
LOW
13.83
VOLUME
358.58K
TURNOVER
0
52 WEEK HIGH
38.80
52 WEEK LOW
12.52
MARKET CAP
660.06M
P/E (TTM)
2.053
1D
5D
1M
3M
1Y
5Y
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, May 11, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards t...
GlobeNewswire · 6d ago
--Stifel Adjusts UniQure's Price Target to $37 From $66, Reiterates Buy Rating
MT Newswires · 05/06 05:49
Things Look Grim For uniQure N.V. (NASDAQ:QURE) After Today's Downgrade
One thing we could say about the analysts on uniQure N.V. ( NASDAQ:QURE ) - they aren't optimistic, having just made a...
Simply Wall St. · 05/04 10:08
--Credit Suisse Lowers uniQure's Price Target to $51 from $54, Keeps Outperform Rating
MT Newswires · 05/03 09:55
--SVB Leerink Adjusts uniQure's Price Target to $56 from $71, Keeps Outperform Rating
MT Newswires · 05/03 08:40
--Goldman Sachs Trims Price Target for uniQure N.V to $59 From $60, Maintains Buy Rating
MT Newswires · 05/03 08:37
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including o...
GlobeNewswire · 05/02 20:45
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/02 12:25
More
No Data
Learn about the latest financial forecast of QURE. Analyze the recent business situations of Uniqure through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

36.84%Strong Buy
57.89%Buy
5.26%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average QURE stock price target is 53.06 with a high estimate of 90.00 and a low estimate of 34.00.
High90.00
Average53.06
Low34.00
Current 14.15
EPS
Actual
Estimate
1.293.635.968.30
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 280
Institutional Holdings: 46.79M
% Owned: 100.31%
Shares Outstanding: 46.65M
TypeInstitutionsShares
Increased
62
5.51M
New
36
2.08M
Decreased
62
4.52M
Sold Out
30
1.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.35%
Pharmaceuticals & Medical Research
+1.51%
Key Executives
Chief Executive Officer/Executive Director
Matthew Kapusta
Chief Financial Officer/General Manager
Christian Klemt
Corporate Executive
Ricardo Dolmetsch
Chief Operating Officer
Pierre Caloz
Executive Vice President
Alexander Kuta
Director
Rachelle Jacques
Non-Executive Director
Robert Gut
Non-Executive Independent Director
Madhavan Balachandran
Non-Executive Independent Director
Jack Kaye
Non-Executive Independent Director
David Meek
Non-Executive Independent Director
Leonard Post
Non-Executive Independent Director
Paula Soteropoulos
Non-Executive Independent Director
Jeremy Springhorn
No Data
No Data
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Webull offers kinds of Uniqure NV stock information, including NASDAQ:QURE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QURE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QURE stock methods without spending real money on the virtual paper trading platform.